65 related articles for article (PubMed ID: 9494571)
1. Novel multidrug-resistance modulators, KR-30026 and KR-30031, in cancer cells.
Choi SU; Lee BH; Kim KH; Choi EJ; Park SH; Shin HS; Yoo SE; Jung NP; Lee CO
Anticancer Res; 1997; 17(6D):4577-82. PubMed ID: 9494571
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by novel verapamil analogs in cancer cells.
Choi SU; Lee CO; Kim KH; Choi EJ; Park SH; Shin HS; Yoo SE; Jung NP; Lee BH
Anticancer Drugs; 1998 Feb; 9(2):157-65. PubMed ID: 9510502
[TBL] [Abstract][Full Text] [Related]
3. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity.
Lee BH; Lee CO; Kwon MJ; Yi KY; Yoo SE; Choi SU
Anticancer Drugs; 2003 Feb; 14(2):175-81. PubMed ID: 12569305
[TBL] [Abstract][Full Text] [Related]
5. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
Kim D; Lee IS; Jung JH; Lee CO; Choi SU
Anticancer Res; 1999; 19(5B):4085-90. PubMed ID: 10628358
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein (Pgp) does not affect the cytotoxicity of flavonoids from Sophora flavescens, which also have no effects on Pgp action.
Choi SU; Kim KH; Choi EJ; Park SH; Lee CO; Jung NP; Yoon SK; Ryu SY
Anticancer Res; 1999; 19(3A):2035-40. PubMed ID: 10470145
[TBL] [Abstract][Full Text] [Related]
7. Effects of KR-30035, a novel multidrug-resistance modulator, on the cardiovascular system of rats in vivo and on the cell cycle of human cancer cells in vitro.
Lee BH; Shin HS; Lee CO; Park SH; Yoo SE; Yi KY; Jung NP; Choi SU
Anticancer Drugs; 2000 Jan; 11(1):55-61. PubMed ID: 10757564
[TBL] [Abstract][Full Text] [Related]
8. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
9. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.
Lin JT; Sharma R; Grady JJ; Awasthi S
Drug Metab Dispos; 2001 Feb; 29(2):103-10. PubMed ID: 11159798
[TBL] [Abstract][Full Text] [Related]
10. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Biscardi M; Teodori E; Caporale R; Budriesi R; Balestri F; Scappini B; Gavazzi S; Grossi A
Leuk Res; 2006 Jan; 30(1):1-8. PubMed ID: 16061283
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
12. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells.
Thimmaiah KN; Jayashree BS; Germain GS; Houghton PJ; Horton JK
Oncol Res; 1998; 10(1):29-41. PubMed ID: 9613455
[TBL] [Abstract][Full Text] [Related]
13. Coumarin derivatives with tumor-specific cytotoxicity and multidrug resistance reversal activity.
Kawase M; Sakagami H; Motohashi N; Hauer H; Chatterjee SS; Spengler G; Vigyikanne AV; Molnár A; Molnár J
In Vivo; 2005; 19(4):705-11. PubMed ID: 15999537
[TBL] [Abstract][Full Text] [Related]
14. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
15. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein.
Choi SU; Park SH; Kim KH; Choi EJ; Kim S; Park WK; Zhang YH; Kim HS; Jung NP; Lee CO
Anticancer Drugs; 1998 Mar; 9(3):255-61. PubMed ID: 9625436
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
17. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
18. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
Yadav S; van Vlerken LE; Little SR; Amiji MM
Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
[TBL] [Abstract][Full Text] [Related]
19. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
[TBL] [Abstract][Full Text] [Related]
20. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.
Devalapally H; Duan Z; Seiden MV; Amiji MM
Clin Cancer Res; 2008 May; 14(10):3193-203. PubMed ID: 18483388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
